─ Alma by ResQ Medical
Every life matters.Every minute counts.
ResQ Medical has completed a feasibility study with no device-related adverse events. The pivotal study is now enrolling, FDA IDE is approved, and commercial preparation is underway.
FDA IDE approved
Pivotal enrolling
Commercial preparation
Commercial preparation
underway
RESQ-MEDICAL
ResQ Medical is developing Alma, a next-generation low-vacuum uterine device for the treatment of abnormal bleeding after birth.
Our mission: make Alma the go-to first-line device in every delivery room, so medical teams can act quickly and confidently when abnormal bleeding occurs, and every mother can return to her baby and family safely, with minimal disruption.
The Need
Balloon-based devices work against the body’s natural contraction mechanism and carry a meaningful risk of failure. The category is moving toward low-vacuum technology and the market is ready for the next generation: stronger performance, simpler use, and reliable anti-clogging operation.
Before undertaking surgical operations, an attempt is made to stop the bleeding using dedicated devices, from which the go to device today is the Uterine balloon Tamponade (UBT) , an expanding balloon that aims to control bleeding by compressing the intrauterine blood vessels.
Alma, the next-generation solution.
Alma is the only multi-layer low-vacuum uterine device, engineered to work with the uterus’s natural contraction to control bleeding while continuously evacuating blood through standard delivery-room wall suction.
The design enables one-handed insertion with no orientation required. Because Alma is introduced similarly to devices already familiar to the delivery-room team, adoption requires only minimal training. Early clinical data shows bleeding control typically achieved within minutes.